



A service of the [U.S. National Library of Medicine](#)
and the [National Institutes of Health](#)

Select **19533661**

1: [Pediatr Blood Cancer](#). 2009 Jun 16. [Epub ahead of print]



Non-Hodgkin lymphoma following temozolomide.

[Sharma A](#), [Gupta D](#), [Mohanti BK](#), [Thulkar S](#), [Dwary A](#), [Goyal S](#), [Muzumder S](#), [Das P](#).

Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.

Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma. It increases survival by 2.5 months when used in combination with radiotherapy as an adjuvant therapy in GBM. Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported. We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy. She developed lymphoma 2 months after completing chemoradiotherapy. Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM. *Pediatr Blood Cancer*. (c) 2009 Wiley-Liss, Inc.

PMID: 19533661 [PubMed - as supplied by publisher]
